Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2002 Sep;93(9):1063–1069. doi: 10.1111/j.1349-7006.2002.tb02484.x

Dose‐response Trial of Lactoferrin in Patients with Chronic Hepatitis C

Shuichi Okada 1,✉, Katsuaki Tanaka 5, Tosiya Sato 6, Hideki Ueno 1, Satoru Saito 5, Takuji Okusaka 1, Keiko Sato 2, Seiichiro Yamamoto 3, Tadao Kakizoe 4
PMCID: PMC5927129  PMID: 12359061

Abstract

Hepatitis C virus (HCV) is one of the most common causes of chronic hepatitis. Interferon is presently the only effective treatment for chronic hepatitis C (CH‐C), though its effectiveness is limited. Lactoferrin (LF), which is an 80‐kDa, iron‐binding glycoprotein, has several biological activities including anti‐viral activity, and it was recently reported to inhibit HCV infection in cultured human hepatocytes. The present trial was designed to assess the relationship between the dose of bovine LF (bLF) and the effect of bLF on serum alanine aminotransaminase (ALT) and HCV RNA levels in patients with CH‐C. Forty‐five patients entered at each of the three dose levels (bLF of 1.8, 3.6, and 7.2 g/day) received orally an 8‐week course of bLF. There was no significant relation between the dose of bLF and the effect of bLF on serum ALT or HCV RNA levels. Biochemical (a 50% or greater decrease in the serum ALT level) and virological (a 50% or greater decrease in HCV RNA level) responses were observed in two and four patients, respectively, but all responders relapsed during the follow‐up period after bLF treatment. The bLF treatment was generally well tolerated, and no patient had any serious adverse event. In conclusion, the excellent tolerance and potential anti‐HCV activity of bLF shown in this trial suggest that further trials using a large number of patients are mandatory. We are currently conducting a double‐blind randomized controlled trial comparing bLF with placebo to clarify the anti‐HCV activity of bLF in patients with CH‐C.

Keywords: Lactoferrin, Chronic hepatitis C, Hepatitis C virus, Alanine aminotransaminase

Full Text

The Full Text of this article is available as a PDF (73.4 KB).

REFERENCES

  • 1. ) Di Bisceglie , A. M.Hepatitis C and hepatocellular carcinoma . Hepatology , 26 ( Suppl. 1 ), 34S – 38S ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Takano , S. , Yokosuka , O. , Imazeki , F. , Tagawa , M. and Omata , M.Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients . Hepatology , 21 , 650 – 655 ( 1995. ). [PubMed] [Google Scholar]
  • 3. ) Niederau , C. , Lange , S. , Heintges , T. , Erhardt , A. , Buschikamp , M. , Hurter , D. , Nawrocki , M. , Kruska , L. , Hensel , F. , Petty , W. and Haussingger , D.Prognosis of chronic hepatitis C: results of a large, prospective cohort study . Hepatology , 28 , 1687 – 1695 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Hoofnagle , J. H. and Di Bisceglie , A. M.The treatment of chronic viral hepatitis . N. Engl. J. Med. , 336 , 347 – 356 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Davis , G. L.Current therapy for chronic hepatitis C . Gastroenterology , 118 , S104 – S114 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) McHutchison , J. G. , Gordon , S. C. , Schiff , E. R. , Shiffman , M. L. , Lee , W. M. , Rustgi , V. K. , Goodman , Z. D. , Ling , M. H. , Cort , S. and Albrecht , J. K.Interferon alfa‐2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C . N. Engl. J. Med. , 339 , 1485 – 1492 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Davis , G. L. , Esteban‐Mur , R. , Rustgi , V. , Hoefs , J. , Gordon , S. C. , Trepo , C. , Shiffman , M. L. , Zeuzem , S. , Craxi , A. , Ling , M. H. and Albrecht , J.Interferon alfa‐2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C . N. Engl. J. Med. , 339 , 1493 – 1499 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Poynard , T. , Marcellin , P. , Lee , S. S. , Niederau , C. , Minuk , G. S. , Ideo , G. , Bain , V. , Heathcote , J. , Zeuzem , S. , Trepo , C. and Albrecht , J.Randomised trial of interferon δ2b plus ribavirin for 48 weeks or for 24 weeks versus interferon δ2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus . Lancet , 352 , 1426 – 1432 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Zeuzem , S. , Feinman , S. V. , Rasenack , J. , Heathcote , E. J. , Lai , M.‐Y. , Gane , E. , O'Grady , J. , Reichen , J. , Diago , M. , Lin , A. , Hoffman , J. and Brunda , M. J.Peginterferon alfa‐2a in patients with chronic hepatitis C . N. Engl. J. Med. , 343 , 1666 – 1672 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Heathcote , E. J. , Shiffman , M. L. , Cooksley , G. E. , Dusheiko , G. M. , Lee , S. S. , Balart , L. , Reindollar , R. , Reddy , R. K. , Wright , T. L. , Lin , A. , Hoffman , J. and De Pamphilis , J.Peginterferon alfa‐2a in patients with chronic hepatitis C and cirrhosis . N. Engl. J. Med. , 343 , 1673 – 1680 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Lonnerdal , B. and Iyer , S.Lactoferrin: molecular structure and biological function . Annu. Rev. Nutr. , 15 , 93 – 110 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Levay , P. F. and Viljoen , M.Lactoferrin: a general review . Haematologica , 80 , 252 – 267 ( 1995. ). [PubMed] [Google Scholar]
  • 13. ) Hasegawa , K. , Motsuchi , W. , Tanaka , S. and Dosako , S.Inhibition with lactoferrin of in vitro infection with human herpes virus . Jpn. J. Med. Set. Biol. , 47 , 73 – 85 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Fujihara , T. and Hayashi , K.Lactoferrin inhibits herpes simplex virus type‐1 (HSV‐1) infection to mouse cornea . Arch. Virol. , 140 , 1469 – 1472 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Defer , M. C. , Dugas , B. , Picard , O. and Damais , C.Impairment of circulating lactoferrin in HIV‐1 infection . Cell. Mol. BioL. , 41 , 417 – 421 ( 1995. ). [PubMed] [Google Scholar]
  • 16. ) Harmsen , M. C. , Swart , P. J. , de Bethune , M. P. , Pauwels , R. , De Clercq , E. , The , T. H. and Meijer , D. K.Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro . J. Infect. Dis. , 172 , 380 – 388 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Ikeda , M. , Sugiyama , K. , Tanaka , T. , Tanaka , K. , Sekihara , H. , Shimotohno , K. and Kato , N.Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes . Biochem. Biophys. Res. Commun. , 245 , 549 – 553 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Ikeda , M. , Nozaki , A. , Sugiyama , K. , Tanaka , T. , Naganuma , A. , Tanaka , K. , Sekihara , H. , Shimotohno , K. , Saito , M. and Kato , N.Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells . Virus Res. , 66 , 51 – 63 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Yi , M. , Kaneko , S. , Yu , D. Y. and Murakami , S.Hepatitis C virus envelope proteins bind lactoferrin . J. ViroL , 71 , 5997 – 6002 ( 1997. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. ) Tanaka , K. , Ikeda , M. , Nozaki , A. , Kato , N. , Tsuda , H. , Saito , S. and Sekihara , H.Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study . Jpn. J. Cancer Res. , 90 , 367 – 371 ( 1999. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. ) Japan Society for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy . J. Jpn. Soc. Cancer Ther. , 28 , 101 – 130 ( 1993. ). [Google Scholar]
  • 22. ) Shibuya , M.Adverse drug reaction criteria of the Japan Society for Cancer Therapy . Jpn. J. Cancer Chemother. , 24 , 2036 – 2041 ( 1997. ). [PubMed] [Google Scholar]
  • 23. ) Tsukiyama‐Kohara , K. , Kohara , M. , Yamaguchi , K. , Maki , N. , Toyoshima , A. , Miki , K. , Tanaka , S. , Hattori , N. and Nomoto , A.A second group of hepatitis C viruses . Virus Genes , 5 , 243 – 254 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Tanaka , T. , Tsukiyama‐Kohara , K. , Yamaguchi , K. , Yagi , S. , Tanaka , S. , Hasegawa , A. , Ohta , Y. , Hattori , N. and Kohara , M.Significance of specific antibody assay for genotyping of hepatitis C virus . Hepatology , 19 , 1347 – 1353 ( 1994. ). [PubMed] [Google Scholar]
  • 25. ) Simmonds , P. , McOmish , F. , Yap , P. L. , Chan , S.‐W. , Lin , C. K. , Dusheiko , G. , Saeed , A. A. and Holmes , E. C.Sequence variability in the 5′ non‐coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity . J. Gen. ViroL , 74 , 661 – 668 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Bedossa , P. , Poynard , T.and for The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C . Hepatology , 24 , 289 – 293 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Armstrong , G. L. , Alter , M. J. , McQuillan , G. M. and Margolis , H. S.The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States . Hepatology , 31 , 777 – 782 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Iyer , S. and Lonnerdal , B.Lactoferrin, lactoferrin receptors and iron metabolism . Eur. J. Clin. Nutr. , 47 , 232 – 241 ( 1993. ). [PubMed] [Google Scholar]
  • 29. ) Sykes , J. A. , Thomas , M. J. , Goldie , D. J. and Turner , G. M.Plasma lactoferrin levels in pregnancy and cystic fibrosis . Clin. Chim. Acta , 122 , 385 – 393 ( 1982. ). [DOI] [PubMed] [Google Scholar]
  • 30. ) Baynes , R. , Bezwoda , W. , Bothwell , T. , Khan , Q. and Mansoor , N.The non‐immune inflammatory response: serial changes in plasma iron, iron‐binding capacity, lactoferrin, ferritin and C‐reactive protein . Scand. J. Clin. Lab. Invest. , 46 , 695 – 704 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Hansen , N. E. , Malmquist , J. and Thorell , J.Plasma myeloperoxidase and lactoferrin measured by radioimmunoassay: relations to neutrophil kinetics . Acta Med. Scand. , 198 , 437 – 443 ( 1975. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Olofsson , T. , Olsson , L , Venge , P. and Elgefors , B.Serum myeloperoxidase and lactoferrin in neutropenia . Scand. J. Haematol. , 18 , 73 – 80 ( 1977. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES